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Phosphodiesterase regulates the homeostasis of cAMP and cGMP, which increase
the strength of excitatory neural circuits and/or decrease inhibitory synaptic plasticity.
Abnormally, synchronized synaptic transmission in the brain leads to seizures.
A phosphodiesterase 10A (PDE10A) inhibitor PF-2545920 has recently attracted
attention as a potential therapy for neurological and psychiatric disorders. We
hypothesized that PF-2545920 plays an important role in status epilepticus (SE) and
investigated the underlying mechanisms. PDE10A was primarily located in neurons,
and PDE10A expression increased significantly in patients with temporal lobe epilepsy.
PF-2545920 enhanced the hyperexcitability of pyramidal neurons in rat CA1, as
measured by the frequency of action potentials and miniature excitatory post-synaptic
current. GluA1 and NR2A expression also increased significantly in post-synaptic
densities, with or without SE in rats treated with PF-2545920. The ratio of p-
GluA1/GluA1 increased in the presence of PF-2545920 in groups with SE. Our results
suggest that PF-2545920 facilitates seizure activity via the intracellular redistribution
of GluA1 and NR2A in the hippocampus. The upregulation of p-GluA1 may play an
important role in trafficking GluA1 to post-synaptic densities. The data suggest it
would be detrimental to use the drug in seizure patients and might cause neuronal
hyperexcitability in non-epileptic individuals.
Keywords: PF-2545920, status epilepticus, rat model, GluA1, NR2A
INTRODUCTION
Phosphodiesterases (PDEs), which hydrolyze cyclic AMP (cAMP) and/or cyclic guanosine
monophosphate (cGMP), contain 11 isozymes encoded by 21 genes in mammals (Seeger et al.,
2003; Bender and Beavo, 2006). Phosphodiesterase 10A (PDE10A) degrades both cAMP and cGMP
but has a much higher affinity for cAMP (Soderling et al., 1999; Conti and Beavo, 2007; Francis
et al., 2011). PDE10A is found in different multiple regions of the brain in mammalian species,
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including the striatal neuropil, substantia nigra, hippocampus,
and cortex (Seeger et al., 2003). Several studies have
demonstrated that PDE10A inhibitors upregulate cAMP
and cGMP concentrations in the striatum (Siuciak et al., 2006;
Grauer et al., 2009) and hippocampus (Liddie et al., 2012).
PDE10A is found predominantly in the mammalian brain,
suggesting that it has multiple functions in the central nervous
system (CNS), especially in striatum-dependent behavioral
phenomena (Siuciak et al., 2006; Leuti et al., 2013; Garcia
et al., 2014). Recent studies demonstrated a putative role for
PDE10A in the treatment of neurological and psychiatric
disorders. Numerous PDE10A inhibitors have been verified as
candidate drugs for the treatment of schizophrenia in animal
or preclinical research (Siuciak et al., 2006; Giralt et al., 2013).
PDE10A may be involved in other neurological and psychiatric
disorders, including Huntington’s disease (Leuti et al., 2013;
Ahmad et al., 2014; Niccolini et al., 2015), Parkinson’s disease
(Garcia et al., 2014; Niccolini et al., 2015), addiction (Liddie
et al., 2012; Logrip et al., 2014), and Lesch–Nyhan disease
(Guibinga et al., 2013). PDE10A is also involved in improving
spatial and recognition memories (Rodefer et al., 2012; Giralt
et al., 2013) and appetite regulation (Piccart et al., 2011,
2013). Moreover, inhibitors of PDE10A may be useful for the
treatment or prevention of colorectal cancer (Li et al., 2015).
Cyclic nucleotides, including cAMP and cGMP, act as second
messenger signaling molecules and participate in numerous
cellular functions in the CNS, including neurotransmitter
specification, axon guidance, and refinement of neuronal
connectivity (Averaimo and Nicol, 2014; Mu et al., 2014). In
addition, a previous study showed that activation of the cAMP–
PKA pathway increases excitability and enhances epileptiform
activity in vitro (Boulton et al., 1993; Chang et al., 2010; Lee,
2015).
Epilepsy is a human brain disorder characterized by recurrent
seizures. Epilepsy is a devastating neurological disease with a
worldwide prevalence of 1–2% (Hauser et al., 1993). Current
therapies aim to control symptoms but are ineffective in
the 20–30% of patients resistant to common antiepileptic
drugs (AEDs) (French, 2007). Epilepsy is caused by many
“insults,” such as trauma, stroke, inflammation, and status
epilepticus (SE) (Duncan et al., 2006). These “insults” lead
to progressive changes in brain structure and function and
an imbalance of excitatory and inhibitory pathways (Curia
et al., 2008). Aberrant excitatory synapses may result in
neuronal hyperexcitability and recurrent seizures (Scharfman,
2007). SE, as a brain insult, can induce “epileptogenesis”
(Loscher and Brandt, 2010). SE and hyperexcitability of neurons
must be minimized. However, the molecular mechanisms
underlying the pathogenesis of SE and epilepsy are not
clear.
Papaverine, an intrinsic inhibitor of PDE10A, has been
reported to cause seizures (Carhuapoma et al., 2001; Kahramaner
et al., 2014), and the cAMP–PKA pathway plays a role in
neuronal excitability of neurons (Boulton et al., 1993; Chang
et al., 2010; Lee, 2015). Based on these data, we hypothesized
that the PDE10A inhibitor PF-2545920 plays an important role
in SE.
MATERIALS AND METHODS
Subjects and Ethics
Adult male Sprague-Dawley (SD) rats from the Laboratory
Animal Center of Chongqing Medical University weighing
200–230 g were used. Rats received water and food ad libitum
and were maintained in a temperature-controlled, 12-h light/dark
environment. Rats were randomly divided into experimental
and control groups. All experiments were performed during the
light phase, and the Chongqing Medical University Commission
for Ethics of Experiments approved all procedures, which were
conducted in accordance with international standards.
Twenty temporal neocortical samples from patients and ten
control samples were randomly obtained from our human brain
bank. Informed consent was obtained from patients and their
lineal relatives. All protocols related to human subjects complied
with the guidelines established by the Committee on Human
Research at Chongqing Medical University and the National
Institutes of Health. Detailed history, neurological examination,
electroencephalogram (EEG) and neuroradiological studies were
performed before surgery. Two or more neurologists diagnosed
each patient, and the diagnosis of epilepsy was complied with
the 1981 International Classification of Epileptic Seizures by
the International League Against Epilepsy. All patients were
refractory to maximal doses of three or more AEDs and required
surgery. Normal temporal neocortex samples were obtained from
patients diagnosed with brain trauma and no history of epilepsy
or AEDs, who underwent neurosurgical intervention because
of head trauma. Tables 1, 2 summarize the clinical features
of temporal lobe epilepsy (TLE) patients and control subjects,
respectively.
Drugs
2-((4-(1-Methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl) phenoxy)
methyl) quinoline (PF-2545920, CAS NO: 1292799-56-4) was
purchased from Selleck (Houston, TX, USA), dissolved in DMSO
and diluted in 0.9% normal saline (NS). PF-2545920 or solvent
control was administered intracerebroventricularly via a cannula
(i.c.v., 0.02 µL/min, 10 µL) 30 min before behavior evaluation.
Sample Preparation
Rats were anesthetized fully and decapitated 2 h after
behavioral studies. Half of the rat or human brain tissues
were placed in liquid nitrogen for Western blotting, and the
remaining tissue was embedded in 4% paraformaldehyde for
immunofluorescence.
Surgical Process
The procedure used for intracerebroventricular cannulation and
electrode implanting, with minor modifications, was described
previously (Logrip et al., 2014; Xu et al., 2015) with minor
modifications. Anesthetized rats were fixed in a stereotaxic
apparatus (RWD Life Science, Co., Ltd, Shenzhen, China). The
site of the left lateral ventricle was located using Paxinos and
Watson: AP = 1.0 mm; ML = 1.5 mm on the left side;
DV = 3.5 mm from the dura. A microwire array (a 2 × 8 array
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TABLE 1 | Clinical characteristics of TLE patients.
Patients Age (y) Sex (M/F) Course (y) AEDs before surgery Pathology Resection tissue
1 28 M 12 CBZ, PHT, TPM Gliosis TNr
2 25 F 10 OXC, CBZ, VPA, PHT Gliosis TNl
3 33 F 15 LTG, TPM, PHT NL TNl
4 25 F 11 CBZ, LTG, TPM, PHT Gliosis TNr
5 20 M 13 VPA, CBZ, PB, PHT, LEV NL TNl
6 30 F 8 CBZ, VPA, PB, TPM Gliosis TNr
7 21 M 11 PB, CBZ, LEV, VPA, PHT NL TNl
8 23 M 10 PHT, CBZ, PB, VPA Gliosis TNl
9 26 M 12 CBZ, VPA, PB, TPM NL TNl
10 29 M 20 CBZ, VPA, TPM, LEV NL TNl
11 47 M 23 CBZ, VPA, PB, TPM, LTG Gliosis TNl
12 40 F 30 VPA, CBZ, PB, PHT NL TNl
13 19 M 7 OXC, VPA, CBZ, PHT NL TNl
14 28 F 12 PHT, PB, VPA, LEV NL, Gliosis TNr
15 26 M 8 VPA, CBZ, LEV, LTG NL TNr
16 29 F 5 PHT, TPM, LTG, VPA NL TNl
17 33 F 7 LEV, VPA, PHT Gliosis TNr
18 23 M 9 PB, VPA, TPM, LEV, LTG NL TNl
19 30 M 20 OXC, PB, CBZ, LEV Gliosis TNl
20 31 F 15 PB, VPA, PB, TPM, LEV NL TNr
F, female; M, male; y, year; AEDs, antiepileptic drugs; VPA, valproic acid; PB, phenobarbital; CBZ, carbamazepine; PHT, phenytoin; GBP, gabapentin; LTG, lamotrigine;
TPM, topamax; LEV, levetiracetam; OXC, oxcarbazepine; TN, temporal neocortex; l, left; r, right; NL, neuron loss.
of platinum-iridium alloy wire, each wire 25 µm in diameter)
was implanted into the right dorsal hippocampus (location:
AP= 3.6 mm, ML= 2.8 mm, and DV= 3.6 mm). Two reference
screws were implanted in the skull. All accessories were attached
to the skull using cement. The following tests were performed
7 days after surgery and 3 days after environmental adaptation.
Electrophysiology
Local field potentials (LFPs) were filtered (0.1–1000 Hz), 1000×
amplified, and digitized at 4 kHz using an OmniPlex R© D Neural
Data Acquisition System (Plexon, Dallas, TX, USA), as described
previously (Gong et al., 2009; Xu et al., 2015).
Two- to three-week-old male SD rats were used for patch-
clamp experiments. Coronal slices (380 µm thick) were cut using
TABLE 2 | Clinical characteristics of control patients.
Patients Age
(y)
Sex
(M/F)
Etiology
diagnosis
Resection
tissue
Pathology
1 22 M Trauma TNl N
2 30 M Trauma TNr N
3 26 F Trauma TNl N
4 21 F Trauma TNr N
5 38 F Trauma TNl N
6 31 M Trauma TNl N
7 25 M Trauma TNr N
8 22 M Trauma TNr N
9 35 F Trauma TNl N
10 43 M Trauma TNr N
F, female; M, male; y, year; TN, temporal neocortex; l, left; r, right; N, normal.
a vibratome (NVSLM1, Camden Instruments, Loughborough,
UK). Slices were cut at 2◦C in a solution containing the following:
26 mM NaHCO3, 22 mM sucrose, 11 mM glucose, 1 mM
NaH2PO4, 3 mM KCl, 0.5 mM CaCl2, and 7 mM MgCl2 saturated
with 95% O2 and 5% CO2. Slices recovered for 1 h at room
temperature in artificial cerebral spinal fluid (ACSF) (pH 7.4):
1.25 mM NaH2PO4, 124 mM NaCl, 3 mM KCl, 26 mM NaHCO3,
2.5 mM CaCl2, 10 mM glucose, and 1.3 mM MgCl2, saturated
with 95% O2 and 5% CO2 (Tang et al., 2015).
Pyramidal neurons in the hippocampal CA1 area were
chosen for recording using inverted phase contrast microscopy
(Nikon, Japan). Slices were stabilized for at least 5 min prior
to recording after patch rupture. Epileptic discharges were
characterized by activity potentials that manifested as continuous
high-frequency spike discharges compared with activity potential
in Mg2+-ACSF (Sombati and Delorenzo, 1995). To measure
action potentials (APs), glass pipettes were filled with an
internal solution: 17.5 mM KCl, 0.5 mM EGTA, 122.5 mM
K-gluconate, 10 mM HEPES, and 4 mM ATP, pH adjusted
to 7.2 with KOH. The bath solution was Mg2+-free ACSF
with or without PF-2545920 (5 µM) during recording. To
measure miniature excitatory post-synaptic currents (mEPSCs),
glass microelectrodes were filled with the following solution:
17.5 mM CsCl, 10 mM HEPES, 4 mM ATP, 0.5 mM EGTA,
132.5 mM Cs-gluconate, and 5 mM QX-314. Bicuculline (10µM)
and tetrodotoxin (1 µM) were added to the Mg2+-free ACSF
to record mEPSCs. For recording the miniature inhibitory
post-synaptic currents (mIPSCs), glass microelectrodes were
filled with the following solution recordings (pH 7.2, 275–
290 mOsm): 100 mM CsCl, 1 mM MgCl2, 1 mM EGTA, 30 mM
N-methyl-D-glucamine (NMG), 10 mM HEPES, 5 mM MgATP,
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0.5 mM Na2GTP and 12 mM phosphocreatine. Slices were
submerged and continuously perfused with Mg2+-free ACSF
containing 6,7-dinitroquinoxaline-2,3(1H,4H)-dione (DNQX,
20 µM), D-2-amino-5-phosphonovalerate (APV, 40 µM) and
tetrodotoxin (TTX, 1 µM) with or without PF-2545920 (5 µM).
The membrane potential was maintained at −70 mV in voltage-
clamp mode.
Signals were acquired using a Multi Clamp 700B amplifier
(Axon, Sunnyvale, CA, USA) and recorded using pClamp
9.2 software (Molecular Devices, Sunnyvale, CA, USA). All
recordings were filtered at 2 kHz and digitized at 10 kHz.
Data were analyzed using Mini Analysis Software (Version
6.0.3; Synaptosoft, Decatur, GA, USA) and pClamp 9.2 software
(Molecular Devices, Sunnyvale, CA, USA).
Acute Rat Model of Seizures
Extrahippocampal lesions and hippocampus-restricted injuries
in human TLE are comparable to pilocarpine-induced rat models,
which are useful for investigating human TLE (Bonilha et al.,
2010). Lithium chloride (127 mg/kg, i.p., Sigma, USA) and
atropine sulfate (1 mg/kg, i.p.) were administered 20 h and
30 min prior to pilocarpine administration (30 mg/kg, i.p.,
Sigma), respectively. Diazepam (10 mg/kg, i.p.) was administered
after 90 min of SE to terminate the convulsive seizures. Seizure
activities were scored according to Racine’s standard criteria
(Racine, 1972). Rats in the experimental group successfully
kindled (levels 4 or more) and were considered the SE group. The
control group was composed of rats that were not successfully
kindled (levels < 4) and are the non-SE group. Electrographic
seizure was defined as high frequency (>5 Hz), high amplitude
(>2× baseline) and lasting more than 5 s (Palencia et al., 2012).
Subcellular Fraction Preparation and
Western Blot
Hippocampal tissue for subcellular fraction collection was
collected 2 h after SE termination. The tissue was homogenized
in ice-cold Tris-HCl buffer (30 mM, pH 7.4) containing
4 mM EDTA, 1 mM EGTA, 5 mM Na4P2O7, 1 mM Na3VO4,
100µM (NH4)6MO7O24, 25 mM NaF, protease inhibitors (Roche
Applied Science) and phosphatase inhibitors (Sigma-Aldrich).
Homogenates were centrifuged at 700 g for 7 min at 4◦C, and
the supernatants were collected. Pellets were re-suspended and
centrifuged at 4◦C at 700 g for another 7 min. One portion
of supernatants was collected as total homogenates, and other
supernatants were centrifuged at 100,000 g for 1 h at 4◦C. Pellets
were re-suspended in the same buffer containing 0.5% Triton
X-100 and incubated for 30 min at 4◦C. The suspensions were
layered on sucrose (1 M) and centrifuged at 100,000 × g for
1 h at 4◦C. Triton-insoluble material (highly enriched in post-
synaptic densities) sedimented through the sucrose layer and was
re-suspended in the same buffer containing 1% SDS, then stored
at−80◦C (Dong et al., 2015; Zhang et al., 2016).
The same sample amounts (50 µg for total protein and
10 µg for subcellular fractions) were separated using 10%
SDS-PAGE gels and transferred onto PVDF membranes. The
membranes were blocked with 5% non-fat milk for 1 h at room
temperature and blotted with the following primary antibodies:
PDE10A (1:200, Santa Cruz, CA, USA), GluA1 (1:3000,
Abcam), GluA2 (1:1000, Abcam), NR1 (1:3000, Abcam), NR2A
(1:1000, Millipore), NR2B (1:1000, Millipore), PSD95 (1:500,
Millipore), GABRA1 (1:500, Proteintech), p-GluA1 (Ser845,
1:1000, Abcam), CaMKII (1:1000, Abcam) and β-actin (1:5000,
Abcam) overnight at 4◦C. The blots were incubated with an HRP-
conjugated goat anti-mouse or anti-rabbit antibody (1:3000) for
1 h at room temperature. The Enhanced Chemiluminescence
Detection System (Amersham ECL) and Bio-Rad ChemiDoc
XRS+ system were used for blot detection and analyses,
respectively. Densitometry quantitation was performed using
Quantity One Software (Bio-Rad Laboratories, Hercules, CA,
USA). Total proteins were normalized to β-actin, and proteins
from subcellular fractions were normalized to the same protein
in total proteins.
Immunofluorescence
Tissue sections (10 µm) were incubated in normal goat
serum (Zhongshan Golden Bridge, Beijing, China) for 30 min
followed by incubation with a mixture containing a PDE10A
antibody (rabbit polyclonal antibody, 1:100), a microtubule-
associated protein 2 (MAP2) antibody (chicken polyclonal
antibody, 1:100, Zhongshan Golden Bridge) and a glial fibrillary
acidic protein (GFAP) antibody (mouse polyclonal antibody,
1:100, Zhongshan Golden Bridge) overnight at 4◦C. Sections
were washed twice in PBS and incubated with a mixture of
DyLight 488-conjugated goat anti-rabbit IgG (1:200, Zhongshan
Golden Bridge), DyLight 549-conjugated goat anti-mouse IgG
(1:200, Zhongshan Golden Bridge) and DyLight 405-conjugated
goat anti-chicken IgG (1:200, Zhongshan Golden Bridge)
in a darkroom for 90 min at 37◦C. Tissue sections were
mounted in 50% glycerol/PBS. Fluorescence was detected
using laser scanning confocal microscopy (Leica Microsystems
Heidelberg GmbH, Germany) on an Olympus IX 70 inverted
microscope (Olympus, Japan) equipped with a Fluoview FVX
confocal scan head. To determine the specificity of antibodies,
PDE10A antibody (488 channel), GFAP antibody (549 channel)
and microtubule-associated protein 2 (MAP2) antibody (405
channel) were replaced by PBS with the same protocols.
Statistical Analysis
The data are presented as means ± SEM. Samples in each
experiment were analyzed in triplicate. One-way ANOVA was
used to compare data from more than two groups (SPSS 19.0).
Paired-samples or independent-samples Student’s t-test were
used for comparing two groups where appropriate. The χ2 test
was used to compare gender differences between TLE patients
and controls. P < 0.05 indicated statistical significance.
RESULTS
Clinical Characteristics of Human
Subjects
The 20 patients (9 females, 11 males) in the TLE group had
a mean age of 28.3 ± 1.489 years and an average disease
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course of 12.9 ± 1.382 years. The 10 cases (four females
and six males) in the control group had a mean age of
29.3 ± 2.367 years. There were no significant differences
in age or sex between the TLE group and control group
(P > 0.05).
PDE10A Expression in the Hippocampus
and Cortex of the Rat Model
Triple-labeled immunofluorescence staining revealed that
PDE10A (green) and MAP2 (blue) were co-expressed in neurons
in the hippocampus and cortex of rat models but not with
GFAP (red) in astrocytes (Figure 1A). We also examined the
levels of PDE10A protein in the hippocampus and cortex of rat
models at different time points after SE using Western blotting
to confirm PDE10A expression in our animal model. PDE10A
expression increased in the hippocampus (Figure 1B, NSE:
0.148 ± 0.025, PSE-6 h: 0.137 ± 0.019, PSE-24 h: 0.217 ± 0.022,
PSE-72 h: 0.224± 0.061; n= 5, P > 0.05) and cortex (Figure 1C,
NSE: 0.174 ± 0.015, PSE-6 h: 0.203 ± 0.015, PSE-24 h:
0.18 ± 0.023, PSE-72 h: 0.198 ± 0.025; n = 5, P > 0.05), but not
significantly. The control group was composed of rats that were
not successfully kindled (levels < 4) and recorded as the non-SE
group.
PDE10A Expression in the Neocortex of
TLE Patients
Data from our animal studies suggested that PDE10A is involved
in the acute seizure model; therefore, we hypothesized that it
may play a role in epilepsy patients. We examined PDE10A
expression using Western blotting and immunofluorescence.
Immunofluorescence staining demonstrated that PDE10A
(green) and MAP2 (blue) are co-expressed in neurons in the
neocortex of TLE patients but not with GFAP (red) in astrocytes
(Figure 2A). Negative control for all channels was shown in the
(Supplementary Material Figure S1). We performed Western
blotting to examine alternations in PDE10A expression in
human sections. PDE10A expression increased significantly
in TLE patients compared with control groups (P < 0.05)
(Figure 2B).
Effect of PF-2545920 on Epileptiform
Discharge and Epileptic Seizure
We performed behavioral and LFP studies to examine whether
the administration of PF-2545920 alone induced spontaneous
seizures and epileptiform discharge. Vehicle or PF-2545920
(50 µM) was administrated and animals were monitored for
6 h (10 µL, i.c.v., n = 5). Vehicle or PF-2545920 alone did not
induce spontaneous seizures or epileptic discharges or any other
abnormalities (Figures 3A,C). We administered PF-2545920
once (50 µM, 10 µL, intracerebroventricularly) (PF-50) prior
to pilocarpine application to examine the role of PF-2545920
in the progression of epileptic seizure. The latency time was
significantly shortened in the PF-50 group compared with the
vehicle group (Figure 3E, 1683.33 ± 118.91 s, n = 9 vs.
2703.13 ± 367.28 s, n = 8; P < 0.05). The cumulative time
was significantly increased in the PF-50 group compared with
FIGURE 1 | PDE10A expression in the hippocampus and cortex of rats. (A) Triple-label immunofluorescence demonstrated that PDE10A (green) and GFAP
(red) were not co-expressed in astrocytes, but PDE10A (green) and MAP2 (blue) were co-expressed in neurons (n = 5). The white squares indicate positive cells in
the cortex or hippocampus of rats. Representative Western blot images of hippocampus (B) and cortex (C) of rats at different time points post-status epilepticus.
PDE10A increased after SE with a trend, but not significantly (non-SE; 6 h post-SE, PSE-6; 24 h post-SE, PSE-24; 72 h post-SE, PSE-72; n = 5, P > 0.05).
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FIGURE 2 | PDE10A expression in the temporal cortex of TLE patients. (A) Triple-label immunofluorescence demonstrated that PDE10A (green) and GFAP
(red) were not co-expressed in astrocytes, but PDE10A (green) and MAP2 (blue) were co-expressed in the neurons of patient cortex (n = 10). The white squares
indicate positive cells. (B) Representative Western blots revealed PDE10A expression in TLE patients and controls. The mean OD ratio of PDE10A relative to β-actin
was significantly higher in the TLE group compared with the control group (∗∗P < 0.01).
the vehicle group (Figure 3F, 2757 ± 109.86 s, n = 9 vs.
1734.38± 321.91 s, n= 8; P < 0.05).
Status epilepticus is characterized by convulsions and the
synchronized discharges of a population of neurons. Therefore,
we used in vivo LFP recording to confirm the effect of PF-50
on LFP. PF-50 treatment dramatically shortened the latency to
full electrographic SE (Figure 3G, 1619.22 ± 117.82 s, n = 9
vs. 2650.13 ± 369.68s, n = 8; P < 0.05). Figures 3B,D show
the typical figures of LFP after pilocarpine with (Figure 3D)
or without (Figure 3B) PF-50. Using the same protocol, we
investigated the effect of different concentrations of PF-2545920
on SE. There was no significant difference in latency time
between the vehicle group and PF group at 10 µM. However,
there was a significant difference between groups treated with
PF-50 µM or PF-100 µM compared with the vehicle group
(Figure 3H, P < 0.01). These results indicate that PF-2545920
exhibits proconvulsant effects in a dose-dependent manner with
a ceiling effect.
PF-2545920 Induced Neuronal
Hyperexcitability
We used whole cell patch-clamp electrophysiology on CA1
pyramidal neurons in rat hippocampal slices perfused with
Mg2+-free ACSF to further evaluate the role of PF-2545920 in
the hippocampus and verify observations from the behavioral
tests. Figure 4A show the typical features of APs, mEPSCs,
and mIPSCs, respectively, in pyramidal neurons before or after
perfusion with PF-2545920 (5 µM). The frequency of APs from
pyramidal neurons after PF-2545920 (5 µM) perfusion increased
significantly compared with the frequency immediately prior to
perfusion with Mg2+-free ACSF (Figure 4B, 4.26 ± 1.19 Hz
vs. 1.86 ± 0.39 Hz; n = 10, P < 0.05). To determine whether
the imbalance of excitatory and inhibitory transmission may
cause neuronal hyperexcitability, we recorded mEPSCs and
mIPSCs. Brain slices perfused with PF-2545920 demonstrated
a significant increase in the frequency of mEPSCs (Figure 4C,
5.92 ± 1.45 Hz vs. 1.50 ± 0.64 Hz; n = 10, P < 0.05).
No significant differences between groups were found in the
amplitude of mEPSCs (Figure 4D) or the frequency (Figure 4E)
or amplitude of mIPSCs (Figure 4F). The corresponding
cumulative fraction of mEPSCs or mIPSCs confirmed our
results. There was no significant difference in the frequency
of AP or the frequency or amplitude of mEPSCs and mIPSCs
prior to perfusion or after washout (Figure 4A, n = 10,
P > 0.05). The electrophysiological data were consistent
with and confirmed the findings of our animal behavior
study.
GluA1 and NR2A Levels Increased in PSD
Total and synaptic NMDAR, AMPAR, and GABAR subunit
compositions are not static but change dynamically in response
to a variety of neuronal activity, including SE (Rajasekaran et al.,
2013; Loddenkemper et al., 2014). Activity dynamically regulates
the functional multiprotein units of the PSD via local protein
turnover (Ehlers, 2003). Imbalance between inhibition and
excitation is one of the main causes of seizures (Scharfman, 2007).
We investigated the total (Figure 5A) and synaptic (Figure 5B)
expression levels of the main subunits of AMPAR (GluA1 and
GluA2), NMDAR (NR1, NR2A, and NR2B) and GABARA1
to delineate the molecular mechanisms linking the inhibition
of PDE10A to the imbalance of excitatory and inhibitory
transmission. We compared subunit expression between vehicle-
treated rats with SE (V-SE group), vehicle-treated rats without
SE (V-non-SE group), PF-50-treated rats with SE (PF-SE group),
and PF-50-treated rats without SE (PF-non-SE group) in total
lysates and their synaptic/total ratio (n = 5 in each group,
one-way ANOVA followed by LSD tests). In total protein
homogenates, the data showed that PF-2545920 did not affect
the levels of GluA1 (V-SE group: 0.7 ± 0.089 vs. PF-SE group:
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FIGURE 3 | Effect of PF-2545920 on epileptic seizure. (A) Representative figure of LFP under the treatment of vehicle alone. (B) Representative recordings of
Licl-Pilocarpine-induced status epilepticus in the vehicle group. (C) Representative figure of LFP under PF-2545920 treatment (50 µM, 10 µL, i.c.v., PF-50).
(D) Representative recordings of Licl-Pilocarpine-induced status epilepticus after PF-2545920 administration (50 µM, 10 µL, i.c.v., PF-50). (E) Behavioral evaluation
revealed that the latency time in the PF-2545920-treated group was significantly decreased compared with the vehicle-treated group (50 µM, 10 µL, i.c.v., PF-50;
n = 8–9, ∗P < 0.05). (F) Behavioral evaluation demonstrated that the cumulative time of generalized tonic clonic seizures in PF-2545920-treated group increased
significantly compared with the vehicle-treated group (50 µM, 10 µL, i.c.v., PF-50; n = 8–9, ∗P < 0.05). (G) EEG evaluation of latency time to full electrographic SE
in PF-2545920-treated group was statistically decreased compared with the vehicle-treated group (50 µM, 10 µL, i.c.v., PF-50; n = 8–9, ∗P < 0.05). (H) Behavioral
evaluation demonstrated that latency time in PF-2545920-treated groups at 50 and 100 µM were statistically decreased compared with the vehicle-treated group
(10 µM, 10 µL, PF-10; 50 µM, 10 µL, PF-50; 100 µM, 10 µL, PF-100; n = 7, ∗∗P < 0.01).
0.486 ± 0.086, P > 0.05; V-non-SE group: 0.4 ± 0.072 vs.
PF-non-SE group: 0.196± 0.028, P> 0.05, Figure 5C). However,
seizures increased the expression of GluA1 (V-SE: 0.7 ± 0.089
vs. V-non-SE: 0.4 ± 0.072; PF-SE: 0.486 ± 0.086 vs. PF-non-SE:
0.196 ± 0.028, P < 0.05). Unexpectedly, PF-2540920 increased
the synaptic/total ratio significantly (V-SE: 0.543 ± 0.08 vs.
PF-SE: 0.799 ± 0.079; V-non-SE: 0.292 ± 0.037 vs.PF-non-SE:
0.742 ± 0.045, P < 0.05, Figure 5D). These results indicate
that PF-2545920 induced the redistribution of GluA1 to post-
synaptic densities. Notably, GluA2 expression was not altered in
total lysates (Figure 5E) or the synaptic/total ratio (Figure 5F,
P > 0.05). The levels of other proteins involved in synaptic
function, including NMDA receptor subunits NR1, NR2A,
and NR2B, were not altered after PF-2545920 treatment in
total lysates (Figures 5G,I,K). No significant differences in the
synaptic/total ratio of NR1 and NR2B were found related to
the effect of PF-2545920 (Figures 5H,L). However, NR2A was
significantly increased in the synaptic/total ratio after PF-2545920
treatment in groups without SE (Figure 5J). The results of the
total lysis suggest that PF-2545920 affected the distribution of
NR2A in the PSD. The primary subunit of GABARs, GABARA1,
was also investigated in homogenates and subcellular fractions.
Although the overall levels of GABARA1 were reduced after
SE, PF-2545920 did not alter the distribution of GABARA1
(Figures 5M,N), which was consistent with our findings using
whole cell patch-clamp. These data demonstrated significant
alterations in GluA1 and NR2A in the subcellular fractions,
further supporting our electrophysiological data and correlating,
in part, with our behavioral data.
p-GluA1 and CaMKII Expression in Rat
Hippocampus
PF-2545920 affects the phosphorylation of GluA1 at Ser845
(p-GluA1Ser845) (Grauer et al., 2009). Our study demonstrated
that the ratio of p-GluA1Ser845/GluA1 in PF-SE was significantly
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FIGURE 4 | PF-2545920 increases the excitability of pyramidal neurons in the CA1 region. (A) Representative traces of action potentials (APs), mEPSCs,
mIPSCs before and after the perfusion of PF-2545920. (B) Frequency of APs increased significantly in pyramidal neurons after perfusion of PF-2545920 (data are
means ± SEM, n = 10, ∗P < 0.05). (C) Frequency of mEPSC increased significantly after PF-2545920 perfusion (data are means ± SEM, n = 10, ∗∗P < 0.01), and
its representative cumulative fractions. (D) Amplitude of mEPSC was not altered after PF-2545920 treatment (data are means ± SEM, n = 10, P > 0.05), and its
representative cumulative fractions. (E) Data demonstrated no significant difference in the frequency of mIPSCs after PF-2545920 treatment (data are
means ± SEM, n = 10, P > 0.05), and its representative cumulative fractions. (F) Data revealed no significant difference in the amplitude of mIPSC after
PF-2545920 treatment (data are means ± SEM, n = 10, P > 0.05), and its representative cumulative fractions.
higher than the V-SE group (Figure 6A, 1.135 ± 0.126
vs. 0.679 ± 0.022; n = 5, P < 0.05). Previous studies
have demonstrated that CaMKII participates in the synaptic
modification of synaptic receptors (NMDARs, AMPARs).
Our data revealed that PF-2545920 downregulated CaMKII
expression compared with the non-SE groups (Figure 6B,
0.588± 0.073 vs. 0.93± 0.167; n= 5, P < 0.05).
DISCUSSION
We present the following results in this work: (i) PF-
2545920 exerted proconvulsant effects; (ii) PF-2545920 induced
hyperexcitability of pyramidal neurons in CA1; (iii) PF-2545920
redistributed GluA1 and NR2A to the PSD; (iv) PDE10A
expression increased significantly in TLE patients; and (v)
PF-2545920 upregulated the p-GluA1Ser845/GluA1 ratio.
Our data suggest that PDE10A expression was upregulated in
the cortex of patients with epilepsy. The exact role of upregulated
PDE10A in TLE patients is unknown. We found that PDE10A
was primarily located in neurons in our experimental rat model
and in human patients, which is consistent with a previous
study (Seeger et al., 2003). However, the hippocampus is the
most widely studied brain region in human and experimental
epilepsy (Thom, 2014). Electrophysiology experiments were
performed to examine the effect of PF-2545920 on neuronal
hyperexcitability, revealing that PF-2545920 increased excitatory,
but not inhibitory, synaptic transmission. This imbalance
of excitatory and inhibitory conductance may lead to the
proconvulsant effects of PF-2545920, consistent with a previous
study (Scharfman, 2007).
Synapse formation is essential for the physiology and
pathology of neuronal circuitry in the brain, and its impairment
is a primary cause of epilepsy (Sutula et al., 1988; Rakhade
and Jensen, 2009). The PSD, which contains receptors and
signaling proteins, is the primary structure underlying synaptic
plasticity (Scannevin and Huganir, 2000). Accumulating evidence
reveals that synaptic NMDAR, AMPAR, and GABAR are
not static but change dynamically in response to neuronal
activity. These changes contribute to neuropsychiatric disorders
when the balance is disturbed under pathological conditions
(Lau and Zukin, 2007). Russwurm et al. (2015) found that
in the striatum, PDE10A acts as a post-synaptic signaling
element and is co-immunoprecipitated with PSD95 and NMDA
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FIGURE 5 | Effect of PF-2545920 on AMPAR, NMDAR, and GABAR expression in total homogenates and post-synaptic densities. Western blot analyses
of hippocampus extracts from rats across groups: vehicle-treated rats with SE group (V-SE), vehicle-treated rats without SE group (V-non-SE), PF-2545920 (50 µM,
10 µL) (PF-50)-treated rats with SE group (PF-SE), and PF-50 treated rats without SE group (PF-non-SE). (A) Representative Western blots of total tissue
homogenates. (B) Representative Western blots of subcellular fractions. (C) SE significantly increased GluA1 expression in total homogenates with or without SE.
There was no significant difference in GluA1 expression between groups with or without PF-2545920 treatment. (D) The ratio of synaptic/total GluA1 increased
significantly in the PF-2545920-treated group compared with the vehicle-treated group with or without SE. (E) There was no significant difference in GluA2
expression between groups treated with or without PF or the synaptic/total ratio (F). (G) Seizures significantly decreased NR1 expression in total homogenates.
There was no significant difference between groups treated with or without PF. (H) There was no significant difference in NR1 expression between groups.
(I) Seizures significantly increased NR2A expression in total homogenates. However, there was no significant difference in NR2A expression between groups treated
with PF compared with groups without PF treatment. (J) Seizures significantly decreased the synaptic/total ratio of NR2A. PF significantly increased the
synaptic/total ratio of NR2A between groups without SE. (K) Seizures significantly increased NR2B expression in total homogenates in groups without SE.
(L) Seizures significantly decreased the synaptic/total ratio of NR2B in groups with or without SE. (M) Seizures significantly decreased GABARA1 expression in
groups with SE. (N) There was no significant difference in the synaptic/total ratio of GABARA1 between groups (n = 5, ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001).
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FIGURE 6 | The p-GluA1Ser845/GluA1 ratio and CaMKII in rat hippocampus. (A) Representative Western blot shows that seizures significantly decreased the
ratios of p-GluA1Ser845 relative to GluA1 in total homogenates. PF significantly increased the ratios of p-GluA1Ser845 relative to GluA1 in groups with SE (n = 5,
∗P < 0.05; ∗∗∗P < 0.001). (B) Representative Western blot shows that seizures significantly decreased the expression of CaMKII in total homogenates. PF
significantly decreased the expression of CaMKII in groups without SE (n = 5, ∗P < 0.05; ∗∗P < 0.01).
receptor subunits. Notably, biochemical data showed that
GluA1 and NR2A were trafficked to the PSD after PF-2545920
treatment and electrophysiological data showed an increase of
mEPSCs. We combined biochemical and electrophysiological
research methods because the biochemical results allowed
us to identify specific changes in the receptor while the
electrophysiological data provided the direct evidence of
neuronal hyperexcitability. There was no significant difference
in GluA2 levels among the treatment and control groups. This
result is somewhat surprising because it has been suggested
that increased levels of synaptic GluA2 homomeric AMPAR
are important for SE (Rajasekaran et al., 2012). The exact
mechanisms are not clear, but a growing body of evidence
has convincingly demonstrated that AMPARs lacking GluA2
exhibit distinct biophysical characteristics, including greater
conductance, calcium permeability, and inwardly rectifying
currents (Zaccara et al., 2013). A prior study demonstrated that
the selective activation of NR2A-containing NMDARs increases
BDNF gene expression, which contributes to the development of
epilepsy (Chen et al., 2007). However, SE in rats or patients affects
the surface expression of GluA1 and NR2A or other subunits
(Rajasekaran et al., 2013; Loddenkemper et al., 2014). Therefore,
the aberrant trafficking of GluA1- and NR2A-containing
receptors may be attributable to SE or/and PF-2545920. Data
from our biochemical and behavioral experiments suggest that
the proconvulsant effects are attributable to the redistribution
of GluA1- and NR2A-containing receptors mediated by PF-
2545920.
GluA1 contains phosphorylation sites for CaMKII, PKC
and PKA, which regulate its synaptic insertion (Anggono
and Huganir, 2012). We examined p-GluA1 expression to
uncover the mechanism regulating redistribution of GluA1.
Our experiments demonstrated a significant increase in
p-GluA1Ser845 after PF-2545920 treatment. This result is
consistent with a previous study demonstrating that a PDE10A
inhibitor regulated the phosphorylation state of presynaptic- or
post-synaptic-associated complexes (Nishi et al., 2008). Notably,
GluA1 phosphorylation may participate in neurotransmitter
transmission and strengthening of seizure activity via the
potentiation of currents induced through AMPA receptors
(Benke et al., 1998; Derkach et al., 1999). CaMKII is a post-
synaptic protein involved in synaptic modification, and it is
critically required for the synaptic recruitment of AMPARs and
NMDARs (Opazo et al., 2010). In addition, Opazo et al. (2010)
showed that exocytosis and/or trapping of AMPAR-containing
vesicles to the PSD in activated synapses may be regulated in
a CaMKII-dependent manner. The expression of CaMKII was
downregulated, which suggests that CaMKII does not play an
important role in the phosphorylation of the GluA1 subunit
after PF-2545920 treatment. However, the downregulation
of CaMKII might prevent GluA1 redistribution to the PSD.
These findings suggest that p-GluA1Ser845 participates in
the redistribution of GluA1 via the cAMP/PKA signaling
pathway. Russwurm et al. (2015) found that in the striatum,
PDE10A is co-immunoprecipitated with PSD95 and NMDA
receptor subunits. Further studies are necessary to reveal the
exact trafficking mechanism of NR2A in our study. However,
NMDARs in the PSD differ in their subunit compositions and are
differentially regulated in response to changes in phosphorylation
(Barria and Malinow, 2002); further studies is required. Previous
study showed that PF-2545920 upregulates cAMP concentration
(Siuciak et al., 2006; Grauer et al., 2009; Liddie et al., 2012), while
cAMP modulate epileptiform after discharge generation in rat
hippocampal slices (Higashima et al., 2002). Our data showed
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PF-2545920 enhances the excitability of pyramidal neurons
and seizure activity possibly via activation of the cAMP–PKA
pathway.
Status epilepticus is a life-threatening form of seizure activity
that represents a major medical emergency associated with
significant morbidity and mortality (Chen and Wasterlain, 2006).
Preclinical studies have recently investigated PF-2545920 as
candidate drug. Volunteers participating in early clinical trials
rarely experience serious injuries, but these events are very
severe when they do occur (Bass et al., 2004). Therefore, it
is essential to identify any proconvulsant activity for drugs
being studied (Porsolt et al., 2002). Additional studies should
be performed to characterize the physiological, pharmacological,
and behavioral actions of PF-2545920 in humans and other
species exposed to this drug. The upregulation of PDE10A
in TLE patients and the trend of upregulation in rats after
SE compared with controls (trauma patients or rats that were
not successfully kindled) might modulate or decrease seizures.
There are some limitations in our study. While no significant
alterations to GluA2-containing receptors were detected, we
cannot exclude the involvement of GluA2-containing AMPARs
in PF-2545920-mediated proconvulsant functions or NR1 and
NR2B. Ethical limitations preclude the absolute acquisition
of absolutely normal brain tissues and human hippocampus
for investigation. Recently, Harada et al. (2017) found an
inhibitor targeting PDE10A, which suppressed seizure frequency.
Although, the precise reasons for this discrepancy remain
unclear, there are some possibilities: (i) The animal model used
in their work, “R6/2 mouse model of Huntington’s disease,” has
a background of neurodegeneration and spontaneous seizures
under stress. In contrast our animal model is a healthy rat
injected with pilocarpine to initiate SE. (ii) Their study, which
shows that repeated treatment with TAK-063 prevents striatal
neurodegeneration, is focused on the mechanism by which
TAK-063 blocks the reduction of BDNF levels. Our study showed
that PF-2545920 enhances the excitability of pyramidal neurons
and seizure activity possibly via activation of the cAMP–PKA
pathway (Boulton et al., 1993; Chang et al., 2010; Lee, 2015).
(iii) TAK-063, which has a faster off-rate, induces similar levels
of activation in medium spiny neurons (MSNs) in the indirect
pathway, while MSNs in the direct pathway are only partially
activated (Suzuki et al., 2016). The role of TAK-603 in the
hippocampus may differ from PF-2545920. If so, TAK-063 is
a better choice for neurological disease and should be studied
further.
CONCLUSION
Our study revealed that PF-2545920 has a robust proconvulsant
effect and induced neuronal hyperexcitability, which is
accompanied by changes in synaptic composition. We also
demonstrated that PF-2545920 enhances the phosphorylation
of GluA1 at Ser845. To our knowledge, this is the
first study to investigate the effects of PF-2545920 on
SE. A full understanding of this drug will guide its
clinical use.
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